Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

Therapeutic options are limited for elderly patients with acute myeloid leukemia (AML). A phase Ib/II study was undertaken to evaluate the maximum-tolerated dose (MTD) and preliminary efficacy of the pan-histone deacetylase inhibitor panobinostat (LBH589) in combination with azacitidine in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, P, Wei, A, Mithraprabhu, S, Cummings, N, Liu, H B, Perugini, M, Reed, K, Avery, S, Patil, S, Walker, P, Mollee, P, Grigg, A, D'Andrea, R, Dear, A, Spencer, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913937/
https://www.ncbi.nlm.nih.gov/pubmed/24413064
http://dx.doi.org/10.1038/bcj.2013.68

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913937/
https://www.ncbi.nlm.nih.gov/pubmed/24413064
http://dx.doi.org/10.1038/bcj.2013.68

Ejemplares similares